Back to search results

A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy

Abroad (travel likely)RecruitingPHASE3

Conditions

Narcolepsy Type 1 (NT1) · Narcolepsy With Cataplexy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Takeda Site 15, Redwood City, California, United States

  • Takeda Site 19, Brandon, Florida, United States

  • Takeda Site 22, Miami, Florida, United States

  • Takeda Site 23, Southfield, Michigan, United States

  • Takeda Site 20, Middletown, New Jersey, United States

  • Takeda Site 24, Durham, North Carolina, United States

  • Takeda Site 25, Winston-Salem, North Carolina, United States

  • Takeda Site 16, Cincinnati, Ohio, United States

  • Takeda Site 18, Cleveland, Ohio, United States

  • Takeda Site 17, Columbia, South Carolina, United States

  • Takeda Site 21, Austin, Texas, United States

  • Takeda Site 1, Montpellier, France

  • Takeda Site 2, Paris, France

  • Takeda Site 3, Toulouse, France

  • Takeda Site 4, Schwerin, Mecklenburg-Vorpommern, Germany

  • Takeda Site 5, Berlin, Germany

  • Takeda Site 6, Bologna, Emilia-Romagna, Italy

  • Takeda Site 7, Rome, Lazio, Italy

  • Takeda Site 8, Heemstede, Netherlands

  • Takeda Site 12, Vitoria-Gasteiz, Alava, Spain

  • Takeda Site 11, Alzira, Valencia, Spain

  • Takeda Site 10, Barcelona, Spain

  • Takeda Site 9, Madrid, Spain

  • Takeda Site 13, Barmelweid, Canton of Aargau, Switzerland

  • Takeda Site 14, Bern, Switzerland

Study leads

  • Study Director

    Takeda

View source on ClinicalTrials.gov(opens in a new tab)